3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
170
Neoplasms
66
Carcinoma, Non-Small-Cell Lung
49
Neoplasm Metastasis
37
Unspecified Adult Solid Tumor, Protocol Specific
25
Ovarian Neoplasms
21
Breast Neoplasms
21
Urinary Bladder Neoplasms
20
Cholangiocarcinoma
20
Lymphoma
19
Colorectal Neoplasms
18
Lymphoma, Non-Hodgkin
17
Lung Neoplasms
17
Sarcoma
16
Hodgkin Disease
14
Fallopian Tube Neoplasms
14
Biliary Tract Neoplasms
13
Lymphoma, Large B-Cell, Diffuse
12
Gallbladder Neoplasms
11
Colonic Neoplasms
11
Carcinoma, Ovarian Epithelial
11
Stomach Neoplasms
10
Recurrence
10
Solid Tumors
9
Bile Duct Neoplasms
8
Adenocarcinoma
8
Triple Negative Breast Neoplasms
7
Small Cell Lung Carcinoma
7
Rectal Neoplasms
7
Melanoma
7
Interventions
tetulomab tetraxetan lu-177
2
osimertinib
2
fludarabine
2
entinostat
2
Pemetrexed
2
Lutetium
2
Carboplatin
2
spartalizumab
1
pembrolizumab
1
nirogacestat
1
interferon gamma-1b
1
gilteritinib
1
ficlatuzumab
1
emvododstat
1
denileukin diftitox
1
atezolizumab
1
Trabectedin
1
Taxes
1
Sunitinib
1
Radiosurgery
1
Oncolytic Virotherapy
1
Nivolumab
1
Lutetium-177
1
Interleukin-2
1
Interferon-gamma
1
Immunotherapy
1
Idarubicin
1
HuMax-IL8
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasms by Histologic Type
×
Gemcitabine
×
Clear all
NCT05494866
2025-03-25
IntenSify
German Cancer Research Center
Phase 1
Terminated
6 enrolled